Brenner David, Ludolph Albert C, Weishaupt Jochen H
Department of Neurology, University of Ulm, Ulm, Germany.
Division of Neurodegenerative Diseases, Neurology Department, University Medicine Mannheim, Mannheim, Germany.
Neurol Res Pract. 2020 Sep 8;2:25. doi: 10.1186/s42466-020-00075-z. eCollection 2020.
Gene selective approaches that either correct a disease mutation or a pathogenic mechanism will fundamentally change the treatment of neurological disorders. Basically, gene specific therapies are designed to manipulate RNA expression or reconstitute gene expression and function depending on the disease mechanism. Considerable methodological advances in the last years have made successful clinical translation of gene selective approaches possible, based on RNA interference or viral gene reconstitution in spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and familial amyloid polyneuropathy (FAP). In this review, we provide an overview of the existing and coming gene specific therapies in neurology and discuss benefits, risks and challenges.
纠正疾病突变或致病机制的基因选择性方法将从根本上改变神经系统疾病的治疗方式。基本上,基因特异性疗法旨在根据疾病机制来操纵RNA表达或重建基因表达及功能。近年来,基于RNA干扰或病毒基因重建技术在脊髓性肌萎缩症(SMA)、杜氏肌营养不良症(DMD)和家族性淀粉样多神经病(FAP)中的应用,方法学取得了显著进展,使得基因选择性方法成功转化为临床应用成为可能。在本综述中,我们概述了神经病学领域现有的和即将出现的基因特异性疗法,并讨论了其益处、风险和挑战。